Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Spray

Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team.

“We are thrilled to expand our executive team and promote Barry as our General Counsel and Raegan as Chief Compliance Officer,” Jeffrey Nau, MMS, PhD, president and chief executive officer of Oyster Point Pharma, said in a company news release. “Our focus at Oyster Point Pharma is to commercialize Tyrvaya (varenicline solution) Nasal Spray and rapidly advance our pipeline forward. Barry and Raegan have significant expertise across the legal and compliance functions within the pharmaceutical industry. We look forward to their counsel as continue to build Oyster Point into a leading company in the eye care space.”

Mr. Barry Rosenfeld

Mr. Rosenfeld brings over 25 years of legal, compliance and leadership experience in the pharmaceutical industry. Prior to Oyster Point he held positions of increasing responsibility within Novartis, most recently as the Vice President, General Counsel and Corporate Secretary of Novartis Finance Corporation. He graduated from New York University School of Law with a J.D. and from the University of Michigan with a B.A. in political science.

Ms. Raegan McClain

Ms. McClain has over 20 years of legal and compliance experience in the pharmaceutical industry at a number of biotech companies, most recently having launch experience at Optinose. Ms. McClain graduated from University of Pittsburgh School of Law with a J.D. and from Penn State University with a B.S. in psychology.